Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06091579 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
A Phase 1 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT06091579 is a Phase 1 study that has completed, run by Insmed Incorporated. The registered enrollment target is 42 participants.
The verdict
NCT06091579, a Phase 1 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of single and multiple doses of treprostinil palmitil inhalation powder in healthy participants.
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06091579
The ClinicalTrials.gov registry entry for NCT06091579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06091579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06091579 about?
NCT06091579 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants". The primary purpose of this study is to evaluate the safety and tolerability of single and multiple doses of treprostinil palmitil inhalation powder in healthy participants.
What is the current status of trial NCT06091579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-09-17. Estimated completion is 2021-01-12.
What interventions are being tested in trial NCT06091579?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT06091579?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.